menu
    • menu
    [{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Reprocell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Dimesna","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Reprocell","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Reprocell"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dimesna","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Dimesna

    Menu

    Dimesna

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lantern Pharma

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Lantern Pharma

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimesna,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Reprocell

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lantern Pharma Selects Reprocell USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

                            Details : Under the agreement, Reprocell will provide support for Lantern Pharma's Phase 2 trial of LP-300 (tavocept) in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with T...

                            Product Name : Tavocept

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 03, 2023

                            Lead Product(s) : Dimesna,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Reprocell

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lantern Pharma

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            Lantern Pharma

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimesna,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in N...

                            Details : LP-300, or tavocept (Disodium 2,2’-dithio-bis-ethane sulfonate), is a small molecule entity with cysteine modifying activity on select proteins, works to modulate multiple cellular pathways simultaneously and is potential first-in-class combination age...

                            Product Name : Tavocept

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 14, 2022

                            Lead Product(s) : Dimesna,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth